Effectiveness of Bivalent Boosters against Severe Omicron Infection.
作者信息
Lin Dan-Yu, Xu Yangjianchen, Gu Yu, Zeng Donglin, Wheeler Bradford, Young Hayley, Sunny Shadia K, Moore Zack
机构信息
University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC
North Carolina Department of Health and Human Services, Raleigh, NC.
出版信息
N Engl J Med. 2023 Feb 23;388(8):764-766. doi: 10.1056/NEJMc2215471. Epub 2023 Jan 25.
Abstract
摘要
相似文献
1
Effectiveness of Bivalent Boosters against Severe Omicron Infection.二价加强针预防奥密克戎严重感染的有效性。
N Engl J Med. 2023 Feb 23;388(8):764-766. doi: 10.1056/NEJMc2215471. Epub 2023 Jan 25.
2
Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study.美国观察性队列研究：COVID-19 疫苗接种和既往 SARS-CoV-2 感染对 12 岁以下儿童感染奥密克戎和严重结局的影响。
Lancet Infect Dis. 2023 Nov;23(11):1257-1265. doi: 10.1016/S1473-3099(23)00272-4. Epub 2023 Jun 16.
3
Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations.田纳西州的疫苗信心与奥密克戎二价加强针接种情况：对弱势群体的影响
Vaccines (Basel). 2023 Apr 27;11(5):906. doi: 10.3390/vaccines11050906.
4
SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.养老院居民接种二价 COVID-19 疫苗后对原始 SARS-CoV-2 株和奥密克戎 BA.1 和 BA.4/BA.5 变异株的 SARS-CoV-2 抗体反应 - 俄亥俄州和罗得岛，2022 年 9 月至 11 月。
MMWR Morb Mortal Wkly Rep. 2023 Jan 27;72(4):100-106. doi: 10.15585/mmwr.mm7204a4.
5
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.二价 SARS-CoV-2 mRNA 疫苗提高中和广度并预防小鼠感染奥密克戎变异株 BA.5。
Nat Med. 2023 Jan;29(1):247-257. doi: 10.1038/s41591-022-02092-8. Epub 2022 Oct 20.
6
Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5.野生型/奥密克戎BA.1二价疫苗作为针对奥密克戎BA.2和BA.5的第二剂加强针的中和抗体反应。
Microbiol Spectr. 2023 Mar 22;11(2):e0513122. doi: 10.1128/spectrum.05131-22.
7
Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters.BA.5二价mRNA疫苗加强针的免疫原性。
bioRxiv. 2022 Oct 25:2022.10.24.513619. doi: 10.1101/2022.10.24.513619.
8
Bivalent Boosters against Severe Omicron Infection.针对奥密克戎严重感染的二价加强针
N Engl J Med. 2023 May 4;388(18):1726. doi: 10.1056/NEJMc2303753.
9
Bivalent Boosters against Severe Omicron Infection. Reply.针对严重奥密克戎感染的二价加强针。回复。
N Engl J Med. 2023 May 4;388(18):1726-1727. doi: 10.1056/NEJMc2303753.
10
Effectiveness of Bivalent Omicron-Containing Booster Vaccines against SARS-CoV-2 Omicron Variant among Individuals with and without Prior SARS-CoV-2 Infection.二价奥密克戎含株加强疫苗对有和无既往 SARS-CoV-2 感染个体的 SARS-CoV-2 奥密克戎变异株的有效性。
Viruses. 2023 Aug 17;15(8):1756. doi: 10.3390/v15081756.
引用本文的文献
1
Single cell phototransfection of mRNAs encoding SARS-CoV2 spike and nucleocapsid into human astrocytes results in RNA dependent translation interference.将编码新冠病毒刺突蛋白和核衣壳蛋白的信使核糖核酸（mRNAs）进行单细胞光转染导入人星形胶质细胞会导致RNA依赖性翻译干扰。
Front Drug Deliv. 2024 Mar 5;4:1359700. doi: 10.3389/fddev.2024.1359700. eCollection 2024.
2
Safety and Immunogenicity of aerosolized adenovirus-vectored COVID-19 vaccine and intramuscular mRNA vaccine bivalent boosters: a randomized open-label clinical trial.雾化腺病毒载体新冠疫苗和肌肉注射mRNA疫苗二价加强针的安全性和免疫原性：一项随机开放标签临床试验。
Nat Commun. 2025 Aug 7;16(1):7281. doi: 10.1038/s41467-025-62698-7.
3
Nanotechnology-based mRNA vaccines.基于纳米技术的mRNA疫苗。
Nat Rev Methods Primers. 2023;3(1). doi: 10.1038/s43586-023-00246-7. Epub 2023 Aug 17.
4
Universal Bacterium-Vectored COVID-19 Vaccine Expressing Early SARS-CoV-2 Conserved Proteins Cross-Protects Against Late Variants in Hamsters.表达早期严重急性呼吸综合征冠状病毒2保守蛋白的通用细菌载体新冠疫苗可交叉保护仓鼠免受晚期变异株感染。
Vaccines (Basel). 2025 Jun 12;13(6):633. doi: 10.3390/vaccines13060633.
5
Estimating population immunity to SARS-CoV-2 by random sampling from primary and secondary healthcare in Scotland, May 2024.2024年5月通过对苏格兰初级和二级医疗保健机构进行随机抽样来评估人群对新冠病毒的免疫力。
EBioMedicine. 2025 Jun;116:105760. doi: 10.1016/j.ebiom.2025.105760. Epub 2025 May 16.
6
Effectiveness of a single COVID-19 mRNA vaccine dose in individuals with prior SARS-CoV-2 infection: a systematic review.一剂新冠病毒mRNA疫苗对既往感染过严重急性呼吸综合征冠状病毒2的个体的有效性：一项系统评价
Commun Med (Lond). 2025 May 3;5(1):151. doi: 10.1038/s43856-025-00882-y.
7
Optimal Timing of Vaccination: A Narrative Review of Integrating Strategies for COVID-19, Influenza, and Respiratory Syncytial Virus.疫苗接种的最佳时机：关于新冠病毒、流感和呼吸道合胞病毒综合策略的叙述性综述
Infect Dis Ther. 2025 May;14(5):911-932. doi: 10.1007/s40121-025-01135-0. Epub 2025 Apr 10.
8
mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy adults: a phase 1/2 trial.健康成年人中基于mRNA的季节性流感和SARS-CoV-2多组分疫苗：一项1/2期试验。
Nat Med. 2025 May;31(5):1484-1493. doi: 10.1038/s41591-025-03591-0. Epub 2025 Mar 18.
9
Exploring Temporal and Spatial Characteristics of Serious Adverse Event Reports Following COVID-19 Bivalent Vaccines.探索新冠病毒二价疫苗接种后严重不良事件报告的时空特征。
Res Sq. 2025 Mar 3:rs.3.rs-6096098. doi: 10.21203/rs.3.rs-6096098/v1.
10
Limitations of neutralizing antibody titers in COVID-19 vaccine efficacy trials and a call for additional correlates of protection.新冠疫苗疗效试验中中和抗体滴度的局限性以及对其他保护相关指标的呼吁。
Hum Vaccin Immunother. 2025 Dec;21(1):2473795. doi: 10.1080/21645515.2025.2473795. Epub 2025 Mar 7.
本文引用的文献
1
Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes.基础疫苗和加强疫苗接种以及先前感染与 SARS-CoV-2 感染和严重 COVID-19 结局的关联。
JAMA. 2022 Oct 11;328(14):1415-1426. doi: 10.1001/jama.2022.17876.
2
Effects of Vaccination and Previous Infection on Omicron Infections in Children.疫苗接种和既往感染对儿童奥密克戎感染的影响。
N Engl J Med. 2022 Sep 22;387(12):1141-1143. doi: 10.1056/NEJMc2209371. Epub 2022 Sep 7.
3
Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina.北卡罗来纳州 9 个月期间的新冠疫苗有效性。
N Engl J Med. 2022 Mar 10;386(10):933-941. doi: 10.1056/NEJMoa2117128. Epub 2022 Jan 12.
Zotero 插件